- Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD
- Consultant Diabetes & Endocrinology, Honorary Professor, Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK.
Website | E-mail
Special Issue Introduction
It is my great pleasure to be the guest editor and introduce you to this edition of Metabolism and Target Organ Damage. It is no surprise to the readership of this journal that the incidence and prevalence of diabetes, in particular type 2 diabetes, is increasing. Clinicians looking after those with this condition know of the devastating effect it can have on the individual, their families, and the impact on society in general. With type 2 diabetes, in particular, a vast majority of the costs are incurred in managing the complications, almost all of which can be prevented by aggressive, early control of modifiable risk factors. The landscape for managing diabetes is also changing. With the advent of ever newer classes of agents, and with the development of newer insulin, as well as the advances in technology, it is often hard for those looking after individuals with diabetes to keep up and to know what to use and when and how.
In this edition of the journal, I have invited respected authors from all over the world to discuss the latest updates in their areas of speciality. In particular, looking at the pathophysiology of type 1 diabetes, with ever more research helping to explain the immunological drivers. The goal, of course, is being the prevention of the disease. Newer agents used to treat diabetes are also discussed, as is the use of technology and how that can be used to help the person with diabetes and their carers in managing the condition. In addition to the benefits of metabolic surgery, some of the complications, including foot and eye disease, are highlighted. And finally, cardiovascular disease, with a discussion on the latest outcome trials to summarize who would benefit most from the agents we have at our disposal.
I hope you enjoy reading this edition of the journal.
Participants1. Steve Bain, Institute of Life Science, Swansea University & Clinical Director, Diabetes Research Unit Cymru, Swansea, Wales, UK.
2. Garry John, Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK.
3. Chantal Mathieu, Katholieke Universiteit Leuven UZ Leuven, 60182, Endocrinology, Leuven, Flanders, Belgium.
4. Dimitrios Pournaras, Department of Bariatric Surgery, Musgrove Park Hospital, Taunton, Somerset, UK.
5. Amar Puttanna, Department of Diabetes and Endocrinology, Good Hope Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, UK.
6. Vijay Viswanathan, MV Hospital for Diabetes and Prof. M. Viswanathan Diabetes Research Centre, Chennai, India.
7. Emma Wilmot, Department of Diabetes & Endocrinology, University Hospitals of Derby & Burton NHS Trust, Derby, UK.
8. Kirsty Woods, Exercise Physiologist, Metabolic Health Solutions, Baldivis, Western Australia.
Submission Deadline15 Jul 2022